子痫前期的血管生成因子：潜在的诊断和治疗方法。
Angiogenic factors in preeclampsia: potential for diagnosis and treatment.
机构信息
aDivision of Nephrology/Department of Medicine bMaternal Fetal Medicine/Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):643-50. doi: 10.1097/MNH.0b013e328365ad98.
Abstract
PURPOSE OF REVIEW
The review summarizes new observations of key roles for circulating angiogenic factors in diagnosing, managing, and treating preeclampsia.
RECENT FINDINGS
Alterations in circulating angiogenic factors (soluble fms-like tyrosine kinase-1 and placental growth factor) in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). Measurement of these angiogenic biomarkers further helps differentiate preeclampsia and its complications from other disorders that present with similar clinical profiles. A ratio of soluble fms-like tyrosine kinase-1/placental growth factor greater than 85 appears ideal as the cut-off for both diagnosis and prognosis. There is also evidence that modulating these factors has therapeutic effects, suggesting a future role for angiogenic factors in treatment and prevention of preeclampsia.
SUMMARY
Circulating angiogenic biomarkers help in diagnostic and prognostic profiling of preeclampsia and may facilitate better management of these patients.
摘要
目的综述
本文综述了循环血管生成因子在子痫前期的诊断、治疗中的关键作用的新观察。
最近的发现
子痫前期循环血管生成因子（可溶性 fms 样酪氨酸激酶-1 和胎盘生长因子）的改变与诊断和不良结局相关，尤其是疾病早产（<34 周）时。这些血管生成生物标志物的测量还有助于区分子痫前期及其并发症与其他具有相似临床表现的疾病。可溶性 fms 样酪氨酸激酶-1/胎盘生长因子比值大于 85 似乎是最佳诊断和预后截断值。也有证据表明调节这些因子具有治疗效果，提示血管生成因子在子痫前期的治疗和预防中有一定作用。
总结
循环血管生成生物标志物有助于子痫前期的诊断和预后分析，并可能有助于更好地管理这些患者。
相似文献
1
Angiogenic factors in preeclampsia: potential for diagnosis and treatment.子痫前期的血管生成因子：潜在的诊断和治疗方法。
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):643-50. doi: 10.1097/MNH.0b013e328365ad98.
2
Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.联合生物标志物预测妊娠并发症并重新定义子痫前期：血管生成-胎盘综合征
Hypertension. 2020 Apr;75(4):918-926. doi: 10.1161/HYPERTENSIONAHA.119.13763. Epub 2020 Feb 17.
3
Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis.子痫前期、妊娠蛋白尿以及叠加慢性肾小球肾炎的子痫前期中的循环血管生成因子。
Am J Obstet Gynecol. 2006 Feb;194(2):551-6. doi: 10.1016/j.ajog.2005.08.034.
4
Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.循环血管生成因子失衡与子痫前期及相关疾病的病理生理学。
Am J Obstet Gynecol. 2022 Feb;226(2S):S1019-S1034. doi: 10.1016/j.ajog.2020.10.022. Epub 2020 Oct 20.
5
Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.自动化电化学发光免疫分析法检测可溶性 fms 样酪氨酸激酶 1 和胎盘生长因子循环浓度的变化可预测子痫前期。
J Hypertens. 2012 Nov;30(11):2173-81. doi: 10.1097/HJH.0b013e328357c0c9.
6
[Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians].[胎盘血管生成因子作为子痫前期生物标志物对临床医生的潜在价值]
Nephrol Ther. 2019 Nov;15(6):413-429. doi: 10.1016/j.nephro.2018.10.005. Epub 2019 Mar 30.
7
Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.用于预测慢性高血压孕妇不良结局的血管生成标志物及其纵向变化。
Am J Obstet Gynecol. 2021 Sep;225(3):305.e1-305.e14. doi: 10.1016/j.ajog.2021.03.041. Epub 2021 Apr 1.
8
The role of angiogenic factors in the management of preeclampsia.血管生成因子在子痫前期管理中的作用。
Acta Obstet Gynecol Scand. 2019 Jun;98(6):700-707. doi: 10.1111/aogs.13540. Epub 2019 Feb 22.
9
Circulating angiogenic factors in singleton vs multiple-gestation pregnancies.单胎妊娠与多胎妊娠中的循环血管生成因子
Am J Obstet Gynecol. 2008 Feb;198(2):200.e1-7. doi: 10.1016/j.ajog.2007.08.042.
10
First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.早孕期慢性高血压孕妇血清血管生成及抗血管生成因子预测子痫前期的价值。
Am J Obstet Gynecol. 2020 Apr;222(4):374.e1-374.e9. doi: 10.1016/j.ajog.2019.10.101. Epub 2019 Nov 6.
引用本文的文献
1
MiR-212-3p promotes proliferation and migration of trophoblast in fetal growth restriction by targeting placental growth factor.miR-212-3p 通过靶向胎盘生长因子促进胎儿生长受限滋养细胞的增殖和迁移。
Bioengineered. 2021 Dec;12(1):5655-5663. doi: 10.1080/21655979.2021.1967069.
2
Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age.静脉注射后，金纳米颗粒在怀孕小鼠体内的分布随妊娠期而变化。
Nanomedicine. 2021 Aug;36:102412. doi: 10.1016/j.nano.2021.102412. Epub 2021 Jun 17.
3
Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda.乌干达穆拉戈国家转诊医院孕妇的血管生成因子循环水平及其与先兆子痫的关系。
PLoS One. 2021 May 19;16(5):e0251227. doi: 10.1371/journal.pone.0251227. eCollection 2021.
4
Preeclampsia Risks in Kidney Donors and Recipients.供肾者和受肾者的子痫前期风险。
Curr Hypertens Rep. 2018 Jun 8;20(7):59. doi: 10.1007/s11906-018-0861-3.
5
Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia.胎盘生长因子、可溶性fms样酪氨酸激酶1、可溶性内皮糖蛋白、白细胞介素-6和白细胞介素-16作为子痫前期的生物标志物
Mediators Inflamm. 2016;2016:3027363. doi: 10.1155/2016/3027363. Epub 2016 Oct 5.
6
Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.母体血浆血管生成指数-1（胎盘生长因子/可溶性血管内皮生长因子受体-1）是一种与子宫胎盘灌注不足相关的胎盘病变负担生物标志物：一项纵向病例队列研究。
Am J Obstet Gynecol. 2016 May;214(5):629.e1-629.e17. doi: 10.1016/j.ajog.2015.11.015. Epub 2015 Dec 11.
7
Placental growth factor deficiency is associated with impaired cerebral vascular development in mice.胎盘生长因子缺乏与小鼠脑血管发育受损有关。
Mol Hum Reprod. 2016 Feb;22(2):130-42. doi: 10.1093/molehr/gav069. Epub 2015 Dec 7.
8
The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.利用母体血液中的血管生成生物标志物来识别哪些小于胎龄儿需要早产以及哪些母亲会发生先兆子痫。
J Matern Fetal Neonatal Med. 2016;29(8):1214-28. doi: 10.3109/14767058.2015.1048431.
9
MiR-519d-3p suppresses invasion and migration of trophoblast cells via targeting MMP-2.微小RNA-519d-3p通过靶向基质金属蛋白酶-2抑制滋养层细胞的侵袭和迁移。
PLoS One. 2015 Mar 24;10(3):e0120321. doi: 10.1371/journal.pone.0120321. eCollection 2015.
10
Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study.一项纵向研究表明，随后发生早发型子痫前期的患者，其母血胎球蛋白-A浓度低于正常妊娠患者。
J Matern Fetal Neonatal Med. 2015;28(11):1260-1269. doi: 10.3109/14767058.2014.954242. Epub 2014 Sep 29.
本文引用的文献
1
Pre-eclampsia and the risk of kidney disease.子痫前期与肾脏疾病风险
Lancet. 2013 Jul 13;382(9887):104-6. doi: 10.1016/S0140-6736(13)60741-2. Epub 2013 May 31.
2
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile.血管生成谱正常的子痫前期的临床特征及结局
Hypertens Pregnancy. 2013 May;32(2):189-201. doi: 10.3109/10641955.2013.784788.
3
Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective.用一种新型检测方法补充当前子痫前期的诊断实践是否能节省费用？从德国医保支付方角度进行建模分析得出的经验教训。
Hypertens Pregnancy. 2013 May;32(2):105-19. doi: 10.3109/10641955.2011.638958.
4
Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia.血清血管生成因子估测用于子痫前期分诊的成本和资源影响。
BJOG. 2013 Sep;120(10):1224-32. doi: 10.1111/1471-0528.12259. Epub 2013 May 7.
5
Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study.足细胞尿发生于子痫前期的蛋白尿和临床特征之前：纵向前瞻性研究。
Hypertension. 2013 Jun;61(6):1289-96. doi: 10.1161/HYPERTENSIONAHA.113.01115. Epub 2013 Mar 25.
6
Pravastatin for the prevention of preeclampsia in high-risk pregnant women.普伐他汀用于预防高危孕妇子痫前期。
Obstet Gynecol. 2013 Feb;121(2 Pt 1):349-353. doi: 10.1097/AOG.0b013e31827d8ad5.
7
Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study.妊娠高血压疾病与终末期肾病的关系：一项基于人群的研究。
CMAJ. 2013 Feb 19;185(3):207-13. doi: 10.1503/cmaj.120230. Epub 2013 Jan 21.
8
Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.妊娠晚期母体血浆血管生成/抗血管生成因子水平识别接近足月或足月发生死胎及重度晚期子痫前期的高危患者。
Am J Obstet Gynecol. 2013 Apr;208(4):287.e1-287.e15. doi: 10.1016/j.ajog.2013.01.016. Epub 2013 Jan 17.
9
Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.疑似子痫前期患者中可溶性内皮糖蛋白与标准评估的血浆浓度比较。
PLoS One. 2012;7(10):e48259. doi: 10.1371/journal.pone.0048259. Epub 2012 Oct 26.
10
Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers.慢性肾病可以通过血清生物标志物与先兆子痫进行鉴别诊断。
Kidney Int. 2013 Jan;83(1):177-81. doi: 10.1038/ki.2012.348. Epub 2012 Sep 26.
Zotero 插件